Key result
Implantable cardioverter-defibrillator therapy, family screening, and genetic testing represent major advances in the prevention of sudden cardiac death in young individuals.
ICD therapy, family screening, and genetic testing are highlighted as major advances in preventing sudden cardiac death in young individuals.
May inform risk stratification in young patients; leaves open need for prospective validation.
Sudden cardiac death (SCD) is a tragic and devastating complication of a number of cardiovascular diseases. Although coronary artery disease accounts for a majority of these deaths across all ages, many other aetiologies contribute to this problem when it occurs in the young (age < or = 35 years), where coronary artery disease is far less common. Specifically, genetic heart disorders are an important cause of SCD in the young. While pharmacological therapies have made some impact on prevention of SCD, the introduction of implantable cardioverter-defibrillator (ICD) therapy has been the single major advance in the prevention of SCD in the young. In addition, the awareness that most causes of SCD in the young are inherited, means family screening of relatives of young SCD victims allows identification of previously unrecognised at-risk individuals thereby enabling prevention of SCD in relatives. The role of genetic testing, both in living affected individuals and in the setting of a 'molecular autopsy', is emerging as a key factor in early diagnosis of an underlying cardiovascular genetic disorder. Understanding the genetic basis of SCD, investigating the molecular mechanisms that lead from the gene defect to the clinical phenotype, and elucidating the specific environmental triggers for SCD, will most likely lead to further key improvements in the prevention of SCD in the young.
No takes yet. Share an insight, caveat, or question.
Shephard et al. (2009) conducted a review in Sudden cardiac death. Implantable cardioverter-defibrillator (ICD) therapy, family screening, and genetic testing was evaluated. Implantable cardioverter-defibrillator therapy, family screening, and genetic testing represent major advances in the prevention of sudden cardiac death in young individuals.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: